1. Home
  2. ITT vs ALNY Comparison

ITT vs ALNY Comparison

Compare ITT & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ITT Inc.

ITT

ITT Inc.

N/A

Current Price

$201.23

Market Cap

19.2B

Sector

Industrials

ML Signal

N/A

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

N/A

Current Price

$145.56

Market Cap

21.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ITT
ALNY
Founded
1920
2002
Country
United States
United States
Employees
N/A
115
Industry
Fluid Controls
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.2B
21.6B
IPO Year
1994
2004

Fundamental Metrics

Financial Performance
Metric
ITT
ALNY
Price
$201.23
$145.56
Analyst Decision
Strong Buy
Buy
Analyst Count
14
30
Target Price
$254.92
★ $284.96
AVG Volume (30 Days)
842.2K
★ 3.1M
Earning Date
11-04-2026
10-29-2026
Dividend Yield
★ 0.75%
N/A
EPS Growth
N/A
★ 206.88
EPS
3.21
★ 18.42
Revenue
★ $3,938,500,000.00
$1,037,418,000.00
Revenue This Year
$41.62
$46.31
Revenue Next Year
$9.56
$17.44
P/E Ratio
$64.26
★ $8.02
Revenue Growth
8.48
★ 22.88
52 Week Low
$166.96
$146.51
52 Week High
$230.32
$479.79

Technical Indicators

Market Signals
Indicator
ITT
ALNY
Relative Strength Index (RSI) 46.53 26.11
Support Level $185.86 N/A
Resistance Level $218.63 $168.35
Average True Range (ATR) 8.02 7.80
MACD -0.42 0.38
Stochastic Oscillator 26.29 3.80

Price Performance

Historical Comparison
ITT
ALNY

About ITT ITT Inc.

ITT began its journey as International Telephone & Telegraph in 1920. Through decades of acquisitions in the mid-1900s, ITT went from manufacturing telephone switching equipment to operating hotels, car rentals, insurance agencies, and bread bakeries. In 1995, the firm split into three separate entities, one of which is the ITT in current operation. After a few more spinoffs in 2011, today ITT sells automotive, industrial, and aerospace products such as brake pads, seals, pumps, valves, connectors, and regulators. It has operations around the globe with notable exposure to North America, Europe, and Asia.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Share on Social Networks: